Mitiglinide Explained

Mitiglinide (INN,^[1] trade name Glufast) is a drug for the treatment of type 2 diabetes.^[2]

Mitiglinide belongs to the meglitinide (glinide) class of blood glucose-lowering drugs and is currently co-marketed in Japan by Kissei and Takeda. The North America rights to mitiglinide are held by Elixir Pharmaceuticals. Mitiglinide has not yet gained FDA approval.

Pharmacology

Mitiglinide is thought to stimulate insulin secretion by closing the ATP-sensitive potassium K_ATP channels in pancreatic β cells.

Dosage

Mitiglinide is delivered in tablet form.

External links

• Elixir Pharmaceuticals — website of the U.S. rights holder for mitiglinide.

Notes and References

1. Web site: International Nonproprietary Names for Pharmaceutical Substances (INN). Recommended International Nonproprietary names (Rec. INN): List 40. World Health Organization. 10 November 2016. 187.
2. Malaisse WJ . Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients . Expert Opinion on Pharmacotherapy . 9 . 15 . 2691–8 . October 2008 . 18803455 . 10.1517/14656566.9.15.2691 . 73318104 .